Quarterly report pursuant to Section 13 or 15(d)

Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details)

v3.20.2
Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Disaggregation of Revenue [Line Items]        
Total revenue $ 2,939 $ 15,132 $ 27,446 $ 29,009
Seagen        
Disaggregation of Revenue [Line Items]        
Total revenue 366 576 9,326 2,005
AstraZeneca        
Disaggregation of Revenue [Line Items]        
Total revenue 2,182 2,903 7,227 12,811
Servier        
Disaggregation of Revenue [Line Items]        
Total revenue $ 391 $ 11,653 $ 10,893 $ 14,193